



US 20200024340A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2020/0024340 A1**
(43) **Pub. Date: Jan. 23, 2020**
Steidl et al.(54) **ANTI-GM-CSF ANTIBODIES****Publication Classification**(71) Applicant: **MORPHOSYS AG**, Martinsried (DE)(51) **Int. Cl.**
C07K 16/24 (2006.01)(72) Inventors: **Stefan Steidl**, Munich (DE); **Elisabeth THOMASSEN-WOLF**, Gauting (DE)(52) **U.S. Cl.**
CPC **C07K 16/243** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/52** (2013.01)(73) Assignee: **MORPHOSYS AG**, Martinsried (DE)(21) Appl. No.: **16/442,779**(57) **ABSTRACT**(22) Filed: **Jun. 17, 2019****Related U.S. Application Data**

(63) Continuation of application No. 15/386,152, filed on Dec. 21, 2016, now Pat. No. 10,377,820, which is a continuation of application No. 12/923,363, filed on Sep. 16, 2010, now Pat. No. 9,751,939, which is a continuation of application No. 11/914,599, filed on Nov. 16, 2007, now Pat. No. 7,867,495, filed as application No. PCT/EP2006/004696 on May 17, 2006.

(60) Provisional application No. 60/682,009, filed on May 18, 2005.

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Specification includes a Sequence Listing.